HighTower Advisors LLC Makes New $484,000 Investment in Ascendis Pharma A/S (NASDAQ:ASND)

HighTower Advisors LLC bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,514 shares of the biotechnology company's stock, valued at approximately $484,000.

Several other institutional investors also recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S in the third quarter valued at approximately $30,000. Jones Financial Companies Lllp boosted its holdings in Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. grew its position in Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 328 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 214 shares during the period. Finally, Sanctuary Advisors LLC bought a new position in shares of Ascendis Pharma A/S during the 4th quarter worth about $203,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a research report on Tuesday, February 18th. Cantor Fitzgerald lifted their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, February 25th. Evercore ISI upped their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, February 18th. The Goldman Sachs Group lifted their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Finally, UBS Group began coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and a consensus target price of $204.64.

Remove Ads

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock traded down $2.06 during trading hours on Thursday, hitting $150.09. 514,466 shares of the stock were exchanged, compared to its average volume of 469,144. The stock has a market capitalization of $9.11 billion, a P/E ratio of -21.14 and a beta of 0.61. The business's 50-day moving average is $146.11 and its two-hundred day moving average is $138.05. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. On average, equities analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.